COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,803 Articles (22,527 medRxiv, 8,276 bioRxiv)

Most recent first Previous |  Page 2448: Articles 24471-24480  | Next

SARS-CoV-2 induces activation and diversification of human plasmacytoid pre-dendritic cells.
Fanny Onodi, Lucie Bonnet-Madin, Léa Karpf, Laurent Meertens, Justine Poirot, Jerôme LeGoff, Constance Delaugerre, Ali AMARA, Vassili Soumelis
10.1101/2020.07.10.197343 — Posted: 2020-07-10
Which animals are at risk? Predicting species susceptibility to Covid-19
Matthew R Alexander, Clara T. Schoeder, Jacquelyn A. Brown, Charles D. Smart, Christopher W. Moth, John P. Wikswo, John Anthony Capra, Jens Meiler, Wenbiao Chen, Meena S. Madhur
10.1101/2020.07.09.194563 — Posted: 2020-07-10
Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis
James Brett Case, Paul Rothlauf, Rita E. Chen, Natasha Kafai, Julie M. Fox, Swathi Shrihari, Broc T. McCune, Ian B. Harvey, Brittany Smith, Shamus Keeler, Louis-Marie Bloyet, Emma S Winkler, Michael J. Holtzman, Daved H. Fremont, Sean P. J. Whelan, Michael S. Diamond
10.1101/2020.07.09.196386 — Posted: 2020-07-10
Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8+ T cells
Anthony Kusnadi, Ciro Ramírez-Suástegui, Vicente Fajardo, Serena J Chee, Benjamin J Meckiff, Hayley Simon, Emanuela Pelosi, Grégory Seumois, Ferhat Ay, Pandurangan Vijayanand, Christian H Ottensmeier
10.1101/2020.07.09.194027 — Posted: 2020-07-10 Discussion: Onsite | Offsite
SARS-CoV-2 infection in the lungs of human ACE2 transgenic mice causes severe inflammation, immune cell infiltration, and compromised respiratory function
Emma S Winkler, Adam L Bailey, Natasha M Kafai, Sharmila Nair, Broc T McCune, Jinsheng Yu, Julie M Fox, Rita E Chen, James T Earnest, Shamus P Keeler, Jon H Ritter, Liang-I Kang, Sarah Dort, Annette Robichaud, Richard Head, Michael J Holtzman, Michael S Diamond
10.1101/2020.07.09.196188 — Posted: 2020-07-10
Molecular analysis of binding region of an ACE2 as a receptor for SARS-CoV-2 between humans and mammals
Takuma Hayashi, Kaoru Abiko, Masaki Mandai, Ikuo Konishi, Nobuo Yaegashi
10.1101/2020.07.09.196378 — Posted: 2020-07-10
A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.
Jeremy D Baker, Rikki L Uhrich, Gerald C Kraemer, Jason E Love, Brian C Kraemer
10.1101/2020.07.10.197889 — Posted: 2020-07-10
Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
Douglas Ferreira Sales-Medina, Ludmila Rodrigues Pinto Ferreira, Lavinia M. D. Romera, Karolina R Goncalves, Rafael V. C. Guido, Gilles Courtemanche, Marcos S. Buckeridge, Edison Luiz Durigon, Carolina B. Moraes, Lucio Freitas Junior
10.1101/2020.07.09.196337 — Posted: 2020-07-10 Discussion: Onsite | Offsite
Inactivation analysis of SARS-CoV-2 by specimen transport media, nucleic acid extraction reagents, detergents and fixatives
Stephen Welch, Katherine Davies, Hubert Buczkowski, Nipunadi Hettiarachchi, Nicole Green, Ulrike Arnold, Matthew Jones, Matthew J Hannah, Reah Evans, Christopher Burton, Jane E Burton, Malcolm Guiver, Patricia A Cane, Neil Woodford, Christine B Bruce, Allen D.G Roberts, Marian J Killip
10.1101/2020.07.08.194613 — Posted: 2020-07-10
A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study
Tien-Tzu Tai, Tzung-Ju Wu, Huey-Dong Wu, Yi-Chen Tsai, Hui-Ting Wang, An-Min Wang, Sheue-Fang Shih, Yee-Chun Chen
10.1101/2020.07.09.196618 — Posted: 2020-07-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).